Ultrahypofractionated Whole Breast Radiation Therapy Using a Novel Boost Regimen for Early-Stage Breast Cancer
Practical Radiation Oncology · 2026-01 · 16 (1) · e1-e16
DOI: 10.1016/j.prro.2025.08.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Practical Radiation Oncology, 2026-01. Verfasst von Molly A Chakraborty und 13 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers New Jersey Medical School, Newark, New Jersey; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: MEMORIAL SLOAN KETTERING CANCER CENTER, National Institutes of Health, National Cancer Institute.
Abstract (Originalsprache)
PURPOSE: The 5-year results of the FAST-Forward trial demonstrated noninferiority of local tumor control using a 26 Gy in 5 fraction regimen compared with 40 Gy in 15 fractions for breast cancer patients receiving adjuvant whole breast radiation therapy (WBRT) with or without a sequential conventionally fractionated tumor bed boost (2 Gy per fraction). Here, we reported our institutional experience using the FAST-Forward regimen with a novel sequential boost regimen of 5.2 Gy in 1 fraction or 10.4 Gy in 2 fractions. METHODS AND MATERIALS: Patients with nonmetastatic invasive breast cancer or ductal carcinoma in situ treated with adjuvant WBRT of 26 Gy in 5 fractions from January 7, 2019, to January 6, 2022, were identified from an institutional database. Clinical outcomes, including adverse events, disease control, and patient-reported outcomes, were collected. Survival outcomes were estimated using the Kaplan-Meier method. Associations between toxicities and clinicopathologic and treatment characteristics were assessed using logistic regression. RESULTS: A total of 311 consecutive patients were included; the use of a 1- or 2-fraction boost was left to the discretion of the treating physicians (54% 1-fraction, 8.7% 2-fraction, and 38% no boost). Median follow-up was 32 months. Overall survival and local recurrence-free survival probabilities at 36 months were 96% (95% CI, 94-99) and 93% (95% CI, 90-97), respectively. Acute and late toxicities occurred at a higher rate in the 2-fraction versus 1-fraction and no boost groups (37.4%, 10.8%, and 12.2% [acute] and 22.7%, 8.6%, and 7.9% [late], respectively). Boost receipt, greater boost volume, 15× energy, increasing breast V95%, and bolus use were associated with the risk of acute grade ≥ 2 toxicities. CONCLUSION: A 5-fraction ultrahypofractionated WBRT regimen for early-stage breast cancer with either no boost or a single-fraction boost of 5.2 Gy resulted in excellent disease control and acceptable toxicity. Increased toxicity was observed with a boost of 10.4 Gy in 2 fractions and is no longer used at our institution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Rutgers New Jersey Medical School, Newark, New Jersey; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York; New York Proton Center, New York, New York. Electronic address: choij3@mskcc.org.
Förderung
- MEMORIAL SLOAN KETTERING CANCER CENTER
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Chakraborty, M. A., Khan, A. J., Tadros, A. B., White, C., Zhang, Z., Kim, M., Xu, A. J., LaPlant, Q., O'Brien, D. R., Cuaron, J. J., Bernstein, M. B., Braunstein, L. Z., Powell, S. N., & Choi, J. I. (2026). Ultrahypofractionated Whole Breast Radiation Therapy Using a Novel Boost Regimen for Early-Stage Breast Cancer. Practical Radiation Oncology, 16(1), e1-e16. https://doi.org/10.1016/j.prro.2025.08.009
Vancouver
Chakraborty MA, Khan AJ, Tadros AB, White C, Zhang Z, Kim M, et al. Ultrahypofractionated Whole Breast Radiation Therapy Using a Novel Boost Regimen for Early-Stage Breast Cancer. Practical Radiation Oncology. 2026;16(1):e1-e16. doi:10.1016/j.prro.2025.08.009
BibTeX
@article{Chakraborty2026,
author = {Chakraborty, Molly A and Khan, Atif J and Tadros, Audree B and White, Charlie and Zhang, Zhigang and Kim, Minji and Xu, Amy J and LaPlant, Quincey and O'Brien, Diana Roth and Cuaron, John J and Bernstein, Michael B and Braunstein, Lior Z and Powell, Simon N and Choi, Jehee Isabelle},
title = {Ultrahypofractionated Whole Breast Radiation Therapy Using a Novel Boost Regimen for Early-Stage Breast Cancer},
journal = {Practical Radiation Oncology},
year = {2026},
volume = {16},
number = {1},
pages = {e1--e16},
doi = {10.1016/j.prro.2025.08.009}
}
EUVIMED